Sign in or create an account to add this stock to your watchlist.
About Amgen (NASDAQ:AMGN)
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor for the treatment of multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound. The company's marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:AMGN
CUSIP03116210
Phone805-447-1000
Debt
Debt-to-Equity Ratio2.14
Current Ratio3.88
Quick Ratio3.60
Price-To-Earnings
Trailing P/E Ratio13.82
Forward P/E Ratio13.08
P/E Growth2.22
Sales & Book Value
Annual Sales$22.85 billion
Price / Sales5.16
Cash Flow$15.4320 per share
Price / Cash11.55
Book Value$23.61 per share
Price / Book7.55
Profitability
EPS (Most Recent Fiscal Year)$12.58
Net Income$1.98 billion
Net Margins9.67%
Return on Equity35.80%
Return on Assets12.06%
Miscellaneous
Employees20,800
Outstanding Shares661,710,000
Amgen (NASDAQ:AMGN) Frequently Asked Questions
What is Amgen's stock symbol?
Amgen trades on the NASDAQ under the ticker symbol "AMGN."
How often does Amgen pay dividends? What is the dividend yield for Amgen?
Amgen announced a quarterly dividend on Wednesday, March 7th. Shareholders of record on Thursday, May 17th will be paid a dividend of $1.32 per share on Friday, June 8th. This represents a $5.28 annualized dividend and a yield of 2.96%. The ex-dividend date of this dividend is Wednesday, May 16th. View Amgen's Dividend History.
How will Amgen's stock buyback program work?
Amgen declared that its board has authorized a stock buyback program on Friday, February 2nd 2018, which authorizes the company to repurchase $10,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase shares of its stock through open market purchases. Shares repurchase programs are generally an indication that the company's board of directors believes its stock is undervalued.
How were Amgen's earnings last quarter?
Amgen (NASDAQ:AMGN) issued its quarterly earnings data on Tuesday, April, 24th. The medical research company reported $3.47 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $3.24 by $0.23. The medical research company had revenue of $5.55 billion for the quarter, compared to the consensus estimate of $5.44 billion. Amgen had a net margin of 9.67% and a return on equity of 35.80%. The business's quarterly revenue was up 1.6% compared to the same quarter last year. During the same quarter last year, the firm earned $3.15 EPS. View Amgen's Earnings History.
When is Amgen's next earnings date?
What guidance has Amgen issued on next quarter's earnings?
Amgen updated its FY18 earnings guidance on Tuesday, April, 24th. The company provided EPS guidance of $12.80-13.70 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $13.47. The company issued revenue guidance of $21.9-22.8 billion, compared to the consensus revenue estimate of $22.71 billion.
What price target have analysts set for AMGN?
22 Wall Street analysts have issued 12-month price targets for Amgen's shares. Their forecasts range from $161.00 to $220.00. On average, they anticipate Amgen's share price to reach $192.1058 in the next twelve months. View Analyst Ratings for Amgen.
What are Wall Street analysts saying about Amgen stock?
Here are some recent quotes from research analysts about Amgen stock:
- 1. According to Zacks Investment Research, "Amgen’s newer drugs – Prolia, Xgeva, Kyprolis – are performing well. Amgen is also progressing with its pipeline and expects approval and launch of migraine candidate, Aimovig this year. Amgen’s restructuring plan is making it leaner and more cost efficient. Lower taxes and share buybacks should provide some bottom-line support in 2018. Amgen’s shares have outperformed the industry this year so far. However, Amgen has some challenges in store, given slowdown in sales of mature drugs like Enbrel, Aranesp and Neulasta, which are facing an array of branded and generic competitors. Volume growth of new drugs may not be enough to offset the lost sales due to the decline in mature brands. Meanwhile, uptake of key new drug, Repatha has been slow due to payer restrictions. However, estimates have gone up ahead of the Q1 earnings release. Amgen has a positive record of earnings surprises in recent quarters." (4/17/2018)
- 2. JPMorgan Chase & Co. analysts commented, "AMGN’s top-line continues to be uninspiring, but the bottom line will meaningfully benefit from a lower than expected tax rate (surprise, surprise) and a large, accelerated $10B share buyback. There are several moving pieces to consider heading into 2018 (which are apparent in management’s uncharacteristically wide guidance range), including timing/magnitude of legacy franchise erosion (e.g., Neulasta & Sensipar), trajectory of recent/upcoming launches (e.g., Kyprolis, Repatha, Aimovig), and the extent to which AMGN chooses to exercise its upsized share repurchase authorization (now ~$14B in total). While we continue to be keenly interested in potential for M&A (which AMGN continues to be constructive on) and the earlier stage pipeline, we maintain our Neutral rating pending evidence of sustainable near-/mid-term growth." (2/4/2018)
- 3. Mizuho analysts commented, "We expect Q4 ’17 trends for both unit demand and net selling price to continue into 2018 – Expect Q1 ’18 sales to be ~ 20% of full year 2018 sales Neulasta US = 969 / 950 / 949 Neulasta Ex-US = 145 / 151 / 152 Neulasta WW = 1114/ 1103 / 1100 Neupogen US = 82 / 87 / 87 PLEASE REFER TO PAGE 5 OF THIS REPORT FOR IMPORTANT DISCLOSURE AND ANALYST CERTIFICATION INFORMATION. Mizuho Securities USA LLC does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision." (2/1/2018)
- 4. Cann analysts commented, "Amgen yesterday announced that the New England Journal of Medicine (NEJM) published positive results from the six-month phase III STRIVE study evaluating Aimovig (erenumab) versus placebo for the prevention of episodic migraine (between four and 14 migraine days per month). The NEJM article reported that Aimovig delivered clinically meaningful and statistically significant differences from placebo for all primary and secondary endpoints in the study." (11/30/2017)
- 5. Argus analysts commented, "We would consider a more constructive stance on AMGN on signs of stronger contributions from the company's new drug pipeline or from its biosimilars portfolio," the firm said."We note, however, that Amgen may not generate commercial revenue from biosimilars until 2019 due to regulatory and legal hurdles." (11/1/2017)
Who are some of Amgen's key competitors?
Some companies that are related to Amgen include Gilead Sciences (GILD), Biogen (BIIB), NOVOZYMES A/S/S (NVZMY), bluebird bio (BLUE), Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), Qiagen (QGEN), AveXis (AVXS), Bio-Techne (TECH), CRISPR Therapeutics (CRSP), arGEN-X BV (ARGX), Spark Therapeutics (ONCE), Halozyme Therapeutics (HALO), China Biologic Products (CBPO) and Atara Biotherapeutics (ATRA).
Who are Amgen's key executives?
Amgen's management team includes the folowing people:
- Mr. Robert A. Bradway, Chairman, CEO & Pres (Age 55)
- Mr. David W. Meline, Exec. VP, CFO and Principal Financial & Accounting Officer (Age 61)
- Mr. Jonathan P. Graham, Sr. VP, Gen. Counsel & Sec. (Age 57)
- Dr. Sean E. Harper, Exec. VP of R&D (Age 55)
- Mr. Anthony C. Hooper, Exec. VP of Global Commercial Operations (Age 63)
Has Amgen been receiving favorable news coverage?
Media stories about AMGN stock have trended somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Amgen earned a media sentiment score of 0.14 on Accern's scale. They also gave media stories about the medical research company an impact score of 45.43 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are Amgen's major shareholders?
Amgen's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.08%), Northern Trust Corp (1.40%), Wells Fargo & Company MN (0.97%), Franklin Resources Inc. (0.61%), LSV Asset Management (0.61%) and Legal & General Group Plc (0.52%). Company insiders that own Amgen stock include Annette Louise Such, Carbonnel Francois De, Cynthia M Patton and Sean E Harper. View Institutional Ownership Trends for Amgen.
Which major investors are selling Amgen stock?
AMGN stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., BlackRock Inc., Wells Fargo & Company MN, Northern Trust Corp, Swiss National Bank, The Manufacturers Life Insurance Company , State of Tennessee Treasury Department and Great Lakes Advisors LLC. Company insiders that have sold Amgen company stock in the last year include Carbonnel Francois De and Sean E Harper. View Insider Buying and Selling for Amgen.
Which major investors are buying Amgen stock?
AMGN stock was acquired by a variety of institutional investors in the last quarter, including Pzena Investment Management LLC, Old Mutual Global Investors UK Ltd., Summit Trail Advisors LLC, SG Americas Securities LLC, Mackay Shields LLC, LSV Asset Management, Element Capital Management LLC and Coho Partners Ltd.. View Insider Buying and Selling for Amgen.
How do I buy shares of Amgen?
Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amgen's stock price today?
One share of AMGN stock can currently be purchased for approximately $178.24.
How big of a company is Amgen?
Amgen has a market capitalization of $117.94 billion and generates $22.85 billion in revenue each year. The medical research company earns $1.98 billion in net income (profit) each year or $12.58 on an earnings per share basis. Amgen employs 20,800 workers across the globe.
How can I contact Amgen?
Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]
MarketBeat Community Rating for Amgen (AMGN)
MarketBeat's community ratings are surveys of what our community members think about Amgen and other stocks. Vote "Outperform" if you believe AMGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
Amgen (NASDAQ:AMGN) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
22 Wall Street analysts have issued ratings and price targets for Amgen in the last 12 months. Their average twelve-month price target is $192.1058, suggesting that the stock has a possible upside of 7.78%. The high price target for AMGN is $220.00 and the low price target for AMGN is $161.00. There are currently 12 hold ratings and 10 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.45 | 2.43 | 2.43 | 2.48 |
| Ratings Breakdown: | 0 Sell Rating(s)
12 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
13 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
13 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
12 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s) |
| Consensus Price Target: | $192.1058 | $190.7505 | $191.8576 | $190.1053 |
| Price Target Upside: | 7.78% upside | 10.34% upside | 10.61% upside | 8.50% upside |
Amgen (NASDAQ:AMGN) Consensus Price Target History
Amgen (NASDAQ:AMGN) Analyst Ratings History
Show:
(Data available from 5/27/2016 forward)
Amgen (NASDAQ:AMGN) Dividend Information
Amgen pays an annual dividend of $5.28 per share, with a dividend yield of 2.96%. AMGN's next quarterly dividend payment will be made on Friday, June 8. The company has grown its dividend for the last 7 consecutive years and is increasing its dividend by an average of 23.50% each year. Amgen pays out 41.97% of its earnings out as a dividend.
| Next Dividend: | 6/8/2018 |
| Annual Dividend: | $5.28 |
| Dividend Yield: | 2.96% |
| Dividend Growth: | 23.50% (3 Year Average) |
| Payout Ratio(s): | 41.97% (Trailing 12 Months of Earnings)
38.74% (Based on This Year's Estimates)
37.39% (Based on Next Year's Estimates)
34.21% (Based on Cash Flow)
|
| Track Record: | 7 Years of Consecutive Dividend Growth |
| Frequency: | Quarterly Dividend |
Amgen (NASDAQ:AMGN) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 3/7/2018 | quarterly | $1.32 | 2.81554951207807% | 5/16/2018 | 5/17/2018 | 6/8/2018 |
| 12/12/2017 | quarterly | $1.32 | 2.98% | 2/14/2018 | 2/15/2018 | 3/8/2018 |
| 10/24/2017 | quarterly | $1.15 | 2.59% | 11/16/2017 | 11/17/2017 | 12/8/2017 |
| 7/28/2017 | quarterly | $1.15 | 2.64% | 8/15/2017 | 8/17/2017 | 9/8/2017 |
| 3/7/2017 | quarterly | $1.15 | 2.59% | 5/15/2017 | 5/17/2017 | 6/8/2017 |
| 12/20/2016 | quarterly | $1.15 | 3.15% | 2/13/2017 | 2/15/2017 | 3/8/2017 |
| 10/14/2016 | quarterly | $1.00 | 2.46% | 11/14/2016 | 11/16/2016 | 12/8/2016 |
| 7/22/2016 | quarterly | $1.00 | 2.4% | 8/15/2016 | 8/17/2016 | 9/8/2016 |
| 3/2/2016 | quarterly | $1.00 | 2.74% | 5/13/2016 | 5/17/2016 | 6/8/2016 |
| 12/15/2015 | quarterly | $1.00 | 2.43% | 2/11/2016 | 2/16/2016 | 3/8/2016 |
| 10/14/2015 | quarterly | $0.79 | 2.07% | 11/12/2015 | 11/16/2015 | 12/7/2015 |
| 7/28/2015 | quarterly | $0.79 | 1.84% | 8/13/2015 | 8/17/2015 | 9/8/2015 |
| 3/4/2015 | quarterly | $0.79 | 1.98% | 5/12/2015 | 5/14/2015 | 6/5/2015 |
| 12/17/2014 | quarterly | $0.79 | 1.88% | 2/10/2015 | 2/12/2015 | 3/6/2015 |
| 10/17/2014 | quarterly | $0.61 | 1.77% | 11/10/2014 | 11/13/2014 | 12/5/2014 |
| 7/25/2014 | quarterly | $0.61 | 1.99% | 8/12/2014 | 8/14/2014 | 9/5/2014 |
| 3/5/2014 | quarterly | $0.61 | 1.96% | 5/13/2014 | 5/15/2014 | 6/6/2014 |
| 12/13/2013 | quarterly | $0.61 | 2.18% | 2/11/2014 | 2/13/2014 | 3/7/2014 |
| 10/16/2013 | quarterly | $0.47 | 1.62% | 11/12/2013 | 11/14/2013 | 12/6/2013 |
| 7/26/2013 | quarterly | $0.47 | 1.72% | 8/14/2013 | 8/16/2013 | 9/6/2013 |
| 3/6/2013 | quarterly | $0.47 | 2.02% | 5/14/2013 | 5/16/2013 | 6/7/2013 |
| 12/13/2012 | quarterly | $0.47 | 2.11% | 2/11/2013 | 2/13/2013 | 3/7/2013 |
(Data available from 1/1/2013 forward)
Amgen (NASDAQ AMGN) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 0.19%
Institutional Ownership Percentage: 78.43%
Amgen (NASDAQ AMGN) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/14/2018 | Sean E. Harper | EVP | Sell | 1,525 | $174.10 | $265,502.50 | |  |
| 4/12/2018 | Sean E. Harper | EVP | Sell | 1,525 | $172.68 | $263,337.00 | | |
| 3/16/2018 | Sean E. Harper | EVP | Sell | 1,525 | $189.75 | $289,368.75 | | |
| 2/14/2018 | Sean E. Harper | EVP | Sell | 1,525 | $174.18 | $265,624.50 | | |
| 1/16/2018 | Sean E. Harper | EVP | Sell | 1,525 | $185.62 | $283,070.50 | | |
| 12/12/2017 | Sean E Harper | EVP | Sell | 1,525 | $176.83 | $269,665.75 | 56,106 | |
| 11/13/2017 | Sean E Harper | EVP | Sell | 1,525 | $171.58 | $261,659.50 | 57,631 | |
| 11/8/2017 | Carbonnel Francois De | Director | Sell | 4,000 | $173.61 | $694,440.00 | | |
| 10/9/2017 | Sean E Harper | EVP | Sell | 1,525 | $185.95 | $283,573.75 | | |
| 5/24/2017 | Cynthia M Patton | SVP | Sell | 2,922 | $154.40 | $451,156.80 | 24,214 | |
| 8/2/2016 | Annette Louise Such | VP | Sell | 3,000 | $174.59 | $523,770.00 | | |
| 5/4/2016 | Madhavan Balachandran | EVP | Sell | 30,000 | $154.12 | $4,623,600.00 | 23,097 | |
| 4/29/2016 | David Baltimore | Director | Sell | 3,312 | $157.21 | $520,679.52 | 32,350 | |
| 4/29/2016 | Sean E Harper | EVP | Sell | 21,875 | $157.99 | $3,456,031.25 | 42,248 | |
| 8/31/2015 | Carbonnel Francois De | Director | Sell | 5,000 | $153.84 | $769,200.00 | 15,150 | |
| 8/19/2015 | Fred Hassan | Director | Buy | 3,010 | $166.63 | $501,556.30 | 3,582 | |
| 6/2/2015 | Cynthia M Patton | SVP | Sell | 4,530 | $157.06 | $711,481.80 | | |
| 4/23/2015 | Stuart A Tross | SVP | Sell | 3,012 | $169.31 | $509,961.72 | | |
| 4/22/2015 | Sean E Harper | EVP | Sell | 28,000 | $171.58 | $4,804,240.00 | | |
| 3/3/2015 | Stuart A Tross | SVP | Sell | 4,415 | $157.74 | $696,422.10 | | |
| 3/2/2015 | David Baltimore | Director | Sell | 3,647 | $158.76 | $578,997.72 | | |
| 2/11/2015 | Robert A Bradway | CEO | Sell | 22,000 | $152.69 | $3,359,180.00 | | |
| 2/5/2015 | Frank C Herringer | Director | Buy | 3,000 | $152.29 | $456,870.00 | | |
| 12/3/2014 | Carbonnel Francois De | Director | Sell | 3,000 | $168.01 | $504,030.00 | | |
| 8/5/2014 | Cynthia M Patton | SVP | Sell | 2,644 | $127.97 | $338,352.68 | | |
| 8/5/2014 | Sean E Harper | EVP | Sell | 14,000 | $127.29 | $1,782,060.00 | | |
| 5/21/2014 | Thomas J.W. Dittrich | CAO | Sell | 4,130 | $112.83 | $465,987.90 | 18,589 | |
| 4/28/2014 | A Kelly Michael | CFO | Sell | 2,065 | $110.45 | $228,079.25 | 41,041 | |
| 3/6/2014 | Carbonnel Francois De | Director | Sell | 1,000 | $126.69 | $126,690.00 | 18,343 | |
| 9/4/2013 | Madhavan Balachandran | EVP | Sell | 18,000 | $112.76 | $2,029,680.00 | | |
| 8/28/2013 | David Baltimore | Director | Sell | 4,582 | $109.66 | $502,462.12 | 26,879 | |
| 5/22/2013 | Thomas J.W. Dittrich | CAO | Sell | 6,130 | $104.78 | $642,301.40 | | |
| 5/21/2013 | Madhavan Balachandran | EVP | Sell | 6,000 | $103.28 | $619,680.00 | | |
| 5/17/2013 | Rebecca M Henderson | Director | Sell | 8,421 | $105.72 | $890,268.12 | | |
| 5/16/2013 | Cynthia M Patton | SVP | Sell | 3,544 | $105.01 | $372,155.44 | | |
| 5/14/2013 | Judith C Pelham | Director | Sell | 25,000 | $108.25 | $2,706,250.00 | | |
(Data available from 1/1/2013 forward)
Amgen (NASDAQ AMGN) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | What Drove Ionis’s Revenue in Q1
finance.yahoo.com - May 25 at 8:09 AM |
| Why this Peninsula startup is primed for an $80.5 million IPO
finance.yahoo.com - May 25 at 8:09 AM |
| Do Alnylam Pharmaceuticals’ Cash Flows Look Healthy?
finance.yahoo.com - May 25 at 8:09 AM |
 | July 6th Options Now Available For Amgen (AMGN)
www.nasdaq.com - May 24 at 5:51 PM |
| Why Is Amgen (AMGN) Up 3.7% Since Its Last Earnings Report?
www.nasdaq.com - May 24 at 5:51 PM |
 | Amgen (AMGN), NCI Enter Pact to Improve Symptom Management During Cancer
www.streetinsider.com - May 24 at 8:12 AM |
| Amgen Enters Groundbreaking Collaboration To Improve Symptom Management During Cancer Treatment
finance.yahoo.com - May 23 at 5:42 PM |
| Amgen Breaks Above 200-Day Moving Average - Bullish for AMGN
www.nasdaq.com - May 23 at 8:02 AM |
 | BRIEF-Amgen Inc Says All Director Nominees Re-Elected To Board
www.reuters.com - May 22 at 5:22 PM |
| Amgen's Label Expansion Application for Prolia Gets FDA Nod
www.nasdaq.com - May 22 at 5:22 PM |
| Amgen Announces Voting Results Of Annual Meeting Of Stockholders
finance.yahoo.com - May 22 at 5:22 PM |
| Regional cycling fans show up in numbers for Amgen Tour (PHOTOS)
finance.yahoo.com - May 22 at 8:01 AM |
| New Migraine Drugs Offer Hope to Sufferers
finance.yahoo.com - May 22 at 8:01 AM |
| Amgen (AMGN) Reports FDA Approval of Prolia (Denosumab) For Glucocorticoid-Induced Osteoporosis
www.streetinsider.com - May 21 at 5:27 PM |
| FDA Approves Prolia® (Denosumab) For Glucocorticoid-Induced Osteoporosis
finance.yahoo.com - May 21 at 5:27 PM |
 | FY2020 Earnings Estimate for Amgen Issued By Leerink Swann (AMGN)
www.americanbankingnews.com - May 21 at 2:00 AM |
 | Amgen Says Just-Approved Migraine Drug Will Cost $6900 a Year
www.bloomberg.com - May 18 at 9:17 AM |
| Today's Research Reports on Trending Tickers: Amgen and Allergan
finance.yahoo.com - May 18 at 9:17 AM |
 | Amgen's first mover advantage with Aimovig bodes well - analysts
seekingalpha.com - May 18 at 8:49 AM |
| Amgen (AMGN) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - May 18 at 1:10 AM |
 | FDA approves new Amgen drug for prevention of migraines
www.cnbc.com - May 17 at 9:48 PM |
| Expanded label for Amgen's Repatha approved in Europe
seekingalpha.com - May 17 at 8:18 AM |
| BRIEF-Amgen Receives European Commission Approval For Repatha (Evolocumab)
www.reuters.com - May 16 at 5:49 PM |
 | Amgen Receives European Commission Approval For Repatha® (Evolocumab) To Prevent Heart Attack And Stroke In ...
www.prnewswire.com - May 16 at 5:49 PM |
| Amgen (AMGN) EVP Sean E. Harper Sells 1,525 Shares
www.americanbankingnews.com - May 15 at 10:10 PM |
| Amgen Inc. (AMGN) Ex-Dividend Date Scheduled for May 16, 2018
www.nasdaq.com - May 15 at 5:40 PM |
| Mizuho Reiterates $200.00 Price Target for Amgen (AMGN)
www.americanbankingnews.com - May 15 at 1:07 PM |
 | Better Buy: Amgen Inc. vs. Biogen Inc.
www.fool.com - May 15 at 8:16 AM |
| Lilly's migraine drug meets main goal in cluster headache trial
finance.yahoo.com - May 15 at 8:00 AM |
| $5.74 Billion in Sales Expected for Amgen (AMGN) This Quarter
www.americanbankingnews.com - May 15 at 4:20 AM |
| NYSE trader: Trump will go easy on drug companies, and stocks should be just fine
finance.yahoo.com - May 13 at 5:58 PM |
| Trump lets drug companies off the hook
finance.yahoo.com - May 13 at 5:58 PM |
| Amgen (AMGN) Expected to Announce Earnings of $3.47 Per Share
www.americanbankingnews.com - May 13 at 8:56 AM |
| Head-To-Head Comparison: BioCryst Pharmaceuticals (BCRX) vs. Amgen (AMGN)
www.americanbankingnews.com - May 11 at 7:31 PM |
| Amgen To Present At The Bank of America Merrill Lynch 2018 Health Care Conference
finance.yahoo.com - May 10 at 5:38 PM |
| Amgen (AMGN) and CRISPR Therapeutics (CRSP) Financial Review
www.americanbankingnews.com - May 9 at 3:12 AM |
 | Amgen, Halliburton, Nvidia, Gold: 'Fast Money' Picks For May 8
www.benzinga.com - May 8 at 8:13 AM |
| Final Trade: AMGN, GLD & more
finance.yahoo.com - May 8 at 8:13 AM |
| Tim's Next Big Idea: Amgen
finance.yahoo.com - May 8 at 8:13 AM |
| How Repatha Is Positioned after 1Q18
finance.yahoo.com - May 8 at 8:13 AM |
| Xgeva Could Significantly Boost Amgen’s Revenue Growth in 2018
finance.yahoo.com - May 7 at 8:01 AM |
| Are These Disappointing Drugs Back on Track to Billions?
finance.yahoo.com - May 5 at 8:10 AM |
| 3 Things In Biotech, May 2: Big CARs, Big Kar Lands, Amgen Advances
seekingalpha.com - May 3 at 8:16 AM |
| Ignore these giant stock buybacks and you'll miss out
finance.yahoo.com - May 3 at 8:16 AM |
| For Expensive New Drugs, Biopharma Should Make Money-Back Guarantees Mandatory
finance.yahoo.com - May 2 at 8:00 AM |
| Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 ASPIRE Study To ...
www.prnewswire.com - April 30 at 5:29 PM |
| Amgen (AMGN) Shares Cross 3% Yield Mark
www.nasdaq.com - April 30 at 5:29 PM |
| UAB-led study shows promise for bone density drug
finance.yahoo.com - April 30 at 5:29 PM |
| Amgen (AMGN) Receives Positive CHMP Opinion to Add OS Results From Phase 3 ASPIRE Study to KYPROLIS Label
www.streetinsider.com - April 30 at 9:24 AM |
| Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 ASPIRE Study To KYPROLIS® (carfilzomib) Label
finance.yahoo.com - April 30 at 9:23 AM |
Amgen (NASDAQ:AMGN) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Amgen (NASDAQ:AMGN) Income Statement, Balance Sheet and Cash Flow Statement
Amgen (NASDAQ AMGN) Stock Chart for Sunday, May, 27, 2018
Loading chart…
